Workflow
片仔癀(600436.SH):温胆片Ⅲ期临床试验完成首例受试者入组

Core Viewpoint - The company Pianzaihuang (600436.SH) has announced the initiation of Phase III clinical trials for its innovative traditional Chinese medicine, Wen Dan Pian, aimed at treating mild to moderate generalized anxiety disorder [1] Group 1: Clinical Trial Details - The Phase III clinical trial for Wen Dan Pian has successfully enrolled its first participant, marking the official start of the trial [1] - The trial is designed as a multicenter, randomized, double-blind, placebo-controlled study, focusing on the efficacy and safety of Wen Dan Pian [1] - The primary efficacy indicator for the trial is the change in HAMA score from baseline after 12 weeks of treatment [1] Group 2: Product Background - Wen Dan Pian is derived from the classic formula Wen Dan Tang, known for its effects in regulating qi, resolving phlegm, and calming the mind [1] - The product targets the specific syndrome of phlegm-heat disturbance, which is associated with anxiety disorders [1]